Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3317415 | Pancreatology | 2014 | 5 Pages |
Abstract
There was no significant difference for preventing PEP between ulinastatin and nafamostat and both drugs were efficacious for preventing post-ERCP complications.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Ji Young Park, Tae Joo Jeon, Mi Won Hwang, Dong Hyun Sinn, Tae-Hoon Oh, Won Chang Shin, Won-Choong Choi,